Browse Categories

Publications by authors named "Guan-Wen Shih"

  • Page 1 of 1
Suitability of boric acid as a boron drug for boron neutron capture therapy for hepatoma.
Yi-Hsuan Hung Yu-Chuan Lin Yu-Ting Lin Guan-Wen Shih Jiunn-Wang Liao

Appl Radiat Isot

October 2020

Hepatoma is the second leading cause of cancer death worldwide. Due to the poor outcomes of patients with late diagnosis, newer treatments for hepatoma are still needed. As an emerging therapy, boron neutron capture therapy (BNCT) may be an effective solution in hepatoma management.

View Article and Find Full Text PDF
Therapeutic Efficacy and Radiobiological Effects of Boric Acid-mediated BNCT in a VX2 Multifocal Liver Tumor-bearing Rabbit Model.
Yi-Hsuan Hung Yu-Chuan Lin Yu-Ting Lin Guan-Wen Shih Jiunn-Wang Liao

Anticancer Res

October 2019

Background/aim: Most patients with hepatocellular carcinoma (HCC) cannot be treated using traditional therapies. Boron neutron capture therapy (BNCT) may provide a new treatment for HCC. In this study, the therapeutic efficacy and radiobiological effects of boric acid (BA)-mediated BNCT in a VX2 multifocal liver tumor-bearing rabbit model are investigated.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Guan-Wen Shih"

  • - Guan-Wen Shih's recent research primarily focuses on the application of boron neutron capture therapy (BNCT) as a novel treatment for hepatoma, a challenging cancer with limited therapeutic options.
  • - The studies highlight the potential of boric acid as an effective boron drug for improving the outcomes of BNCT in hepatoma management, with a specific investigation into its therapeutic efficacy in animal models.
  • - Findings suggest that BA-mediated BNCT may alter the radiobiological effects significantly, opening new avenues for treatment strategies in patients with advanced hepatocellular carcinoma who are not eligible for conventional therapies.

Privacy Policy Site Map

© LitMetric 2025. All rights reserved.